## Microsoft word - lichtenberg seer-medstat paper 2006-12-31.doc

**Pharmaceutical innovation and U.S. cancer survival in the 1990s: **
**evidence from linked SEER-MEDSTAT data **
**Frank R. Lichtenberg **
**Pharmaceutical innovation and U.S. cancer survival in the 1990s: **
**evidence from linked SEER-MEDSTAT data **
**Abstract **
This study examines the impact of pharmaceutical innovation and other factors on
the survival of U.S. cancer patients during the 1990s. In particular, it investigates whether cancer survival rates increased more for those cancer sites that had the largest increases in the proportion of drug treatments that were “new” treatments. We control for “expected survival,” i.e. the survival of a comparable set of people that did not have cancer, thereby measuring the excess mortality that is associated with a cancer diagnosis. We also control for other types of medical innovation, i.e. innovation in surgical procedures, diagnostic radiology procedures, and radiation oncology procedures.
Data on observed and expected survival rates, the number of people diagnosed,
mean age at diagnosis, and stage distribution are obtained from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) 1973-2003 Public-use Data. Estimates of rates of innovation in drugs and other treatment and diagnostic procedures were constructed from the MEDSTAT Marketscan database and other data sources.
We compute weighted least-squares estimates of 12 versions of a survival model,
based on different survival intervals, functional forms, and sets of weights.
The drug vintage coefficient is positive and significant in almost every model.
This indicates that the cancer sites whose drug vintage (measured by the share of post-1990 treatments) increased the most during the 1990s tended to have larger increases in observed survival rates, ceteris paribus. Estimates of the fraction of the 1992-1999 change in the observed survival rate that is attributable to the increased utilization of post-1990 drugs range from 12% to 121%. The estimated fraction is higher for shorter survival intervals, when observations are weighted by the number of MEDSTAT drug treatments, and for the logarithmic specification. The mean of the 12 estimates of the fraction of the 1992-1999 change in the observed survival rate that is attributable to the increased utilization of post-1990 drugs is 44%. Due to sampling and other measurement errors, these estimates may be conservative.
The coefficients on measures of other types of medical innovation (in radiation
oncology, diagnostic radiology, and surgery innovation) are generally not significant. However these measures may be less reliable than the drug innovation measure: they are based upon the year in which the AMA established a new procedure code, which may be a far less meaningful indicator of innovation than the year in which the FDA first approved a drug. This topic warrants further research.
Frank R. Lichtenberg Graduate School of Business Columbia University 614 Uris Hall, 3022 Broadway New York, NY 10027 Phone: (212) 854-4408

[email protected]
Many clinical studies have compared the effects of newer and older drugs on
cancer survival rates.1 The findings of these studies have been mixed. Some studies
have found that use of newer cancer drugs increased survival rates. For example,
Richardson et al (2005) compared bortezomib (FDA approved May 2003) with high-dose
dexamethasone (FDA approved October 1958) in patients with relapsed multiple
myeloma who had received one to three previous therapies. They found that patients
treated with bortezomib had a longer survival than patients treated with dexamethasone:
the one-year survival rate was 80 percent among patients taking bortezomib and 66
percent among patients taking dexamethasone (P=0.003), and the hazard ratio for overall
survival with bortezomib was 0.57 (P=0.001). Similarly, Kantarjian et al (2005)
concluded that imatinib mesylate (FDA approved May 2000) improved survival
compared with other therapies in patients with accelerated-phase chronic myelogenous
Other studies have found that use of newer cancer drugs did not increase survival
rates. For example, von der Maase et al (2005) compared long-term survival in patients
with locally advanced or metastatic transitional cell carcinoma of the urothelium treated
with cisplatin and either gemcitabine (FDA approved May 1996) or
methotrexate/vinblastine/doxorubicin (all of which were approved before 1975). A total
of 405 patients were randomly assigned: 203 to the gemcitabine/cisplatin arm and 202 to
the methotrexate/vinblastine/doxorubicin/cisplatin arm. Overall survival was similar in
This paper will seek to determine the effect of pharmaceutical innovation—the
use of newer drugs—

*in general* on cancer survival rates. A reliable estimate of this effect
can’t be obtained by simply surveying previous clinical studies of specific drugs and
cancer sites, for two reasons. First, there is considerable variation in the methodology
and metrics used in these studies, rendering comparison and aggregation difficult.
1 A PubMed search for (("Survival Rate") AND ("Antineoplastic Agents")) AND ("Comparative Study")) yields 387 items.
Second, these studies may not provide a complete or representative picture; there may be
little or no published evidence about the survival impact of some drugs.2
We will investigate whether cancer survival rates increased more for those cancer
sites that had the largest increases in the proportion of drug treatments that were “new”
treatments. We will control for “expected survival,” i.e. the survival of a comparable set
of people that did not have cancer, thereby measuring the excess mortality that is
associated with a cancer diagnosis. We will also control (imperfectly) for other types of
medical innovation, i.e. innovation in surgical procedures, diagnostic radiology
procedures, and radiation oncology procedures.
Section I of this paper sketches a simple theory of cancer survival. Section II
presents an econometric specification based on this theory. Section III describes the
construction of data used to estimate this model. Estimation issues are discussed in
Section IV. Empirical results are presented in Section V. Section VI contains a summary

**I. A simple theory of cancer survival **
S = observed survival rate E = expected survival rate R = S / E = relative survival rate3 Q = treatment quality P = disease progression at time of diagnosis V = treatment vintage
We postulate the following simple theory of cancer survival: R = S / E = f(Q, P)
where f’Q > 0 and f’P < 0, or, more generally,
where f’E > 0, f’Q > 0 and f’P < 0.
2 Johnson et al (2003) reported that only one-fourth of the oncology drug marketing applications approved by the FDA during the period January 1, 1990 to November 1, 2002 were based on direct evidence of survival benefits; 75% of approvals were based on surrogate end points (e.g. reduction in tumor size). 3 Ederer et al (1961).
The observed survival rate is hypothesized to be an increasing function of expected
survival and the quality of treatment, and a decreasing function of disease progression at
time of diagnosis. Moreover, we hypothesize that treatment quality is an increasing
where f’V > 0. Substituting (3) into (2),
where f’E > 0, f’V > 0 and f’P < 0. The observed survival rate is hypothesized to be an
increasing function of expected survival and treatment vintage, and a decreasing function
of disease progression at time of diagnosis.
Our primary objective is to estimate the effect of treatment vintage (V) on survival
(S). Equation (4) indicates that if P is correlated with V, it is necessary to control
adequately for P to obtain an unbiased estimate of the effect of treatment vintage on
Measuring progression (or severity) of disease is often challenging in health
economics. We will include five variables (or groups of variables) postulated to be
indicators or determinants of the mean progression of disease:
(1)

*Time dummies (“year effects”)*: control for changes in mean disease progression
(2)

*Stage distribution of disease*: the fraction of patients diagnosed with in situ (stage
0), localized/regional (stages 1 and 2),5 and distant (stage 4) cancer.6
(3)

*Vintage of diagnostic radiology procedures*. Use of newer diagnostic radiology
procedures may result in earlier detection, i.e. a reduction in P.
(4)

*Number of people diagnosed* *and mean age at diagnosis*. Improvements in
diagnostic technology are likely to lead to earlier detection. This would result in an increase in the number of people diagnosed and a reduction (or below-average increase) in their mean age.
4 The vintage of a treatment is the year in which the treatment was first used. For example, the vintage of a drug is the year that the drug’s active ingredient was first approved by the FDA. 5 We combine stages 1 and 2 because these two stages are merged in the case of prostate cancer in SEER data. 6 The omitted stage category is “unstaged” (SEER Historic Stage A 9). All lymphomas and leukemias are considered unstaged

**II. Econometric specification **
Based on this theory, we propose the following econometric model of observed
f(Sit) = β1 drug_new%it + β2 rad_onc_new%it + β3 rad_diag_new%it + β4 surg_new%it
+ β5 f(Eit) + β6 ln(Nit) + β7 ageit + β8 in_situ%it + β9 loc_reg%it + β10 distant%it
Sit = the observed survival rate of people diagnosed with cancer
originating at site i in year t. The observed survival rate is the probability of surviving all causes of death for a specified time interval. Observed survival does not consider cause of death, it simply looks at who is alive and who is not.
drug_new%it = % of drug treatments administered in year t associated with
cancer originating at site i that used drugs approved by the FDA after 1990
rad_onc_new%it = % of radiation oncology procedures performed in year t
associated with cancer originating at site i whose CPT codes were established by the American Medical Association (AMA) after 1990
rad_diag_new%it = % of diagnostic radiation procedures performed in year t
associated with cancer originating at site i whose CPT codes were established by the AMA after 1990
surg_new%it = % of surgical procedures performed in year t associated with
cancer originating at site i in year t whose CPT codes were established by the AMA after 1990
Eit = the expected survival rate of people diagnosed with cancer
originating at site i in year t. The expected survival rate is the observed survival rate of a comparable (in terms of race, sex, and age) set of people who do not have cancer.
ageit = the mean age of people diagnosed with cancer originating at site
Nit = the number of people diagnosed with cancer originating at site i
in_situ%it = the fraction of cancers originating at site i in year t that were
loc_reg%it = the fraction of cancers originating at site i in year t that were
diagnosed as localized or regional (stage 1 or 2)
distant%it = the fraction of cancers originating at site i in year t that were
Due to the presence of fixed cancer-site effects and year effects, this is a
difference-in-differences model. A positive and significant estimate of β1 would signify
that there were above-average increases in observed survival rates of cancer sites with
above average increases in drug_new%,

*ceteris paribus*.
Since the expected survival rate is based on the age- (as well as race- and sex-)
distribution of a comparable set of people who do not have cancer, controlling for mean
age as well as expected survival may be redundant.

**III. Data construction **
*Survival data. *Data on observed and expected survival rates, the number of people
diagnosed, mean age at diagnosis, and stage distribution were obtained from the National
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) 1973-2003
Public-use Data. I used data from SEER 9 registries, which are Atlanta, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and
Utah. In this data set, cases diagnosed from 1973 through 2003 are available for all
registries except Seattle-Puget Sound (1974+) and Atlanta (1975+). The database
contains one record for each of 3,260,176 tumors. However, the treatment innovation
measures can only be constructed for the period 1992-2003.
Cancer cases were classified using the SEER Cancer Causes of Death Recode
1969+ (9/17/2004).7 This classification includes 68 non-overlapping types of cancer.
Survival rates may be calculated for a variety of time intervals (1-year, 2-year,
etc.). We will estimate models of 1-year, 2-year, and 3-year survival rates. (The longer
the time interval, the shorter the available time series.) Table 1 shows 1992 and 2000 2-
year survival data for the top 30 (ranked by 1992 incidence) cancer sites, or groups of
cancer sites. The 2-year relative survival rate for all cancer sites combined increased
from 72% in 1992 to 75% in 2000. The 1992-2002 change in survival rates varied
considerably across cancer sites. For example, the relative survival rate for Cervix Uteri
declined from 86% to 81%, while the relative survival rate for Skin excluding Basal and
Squamous increased from 83% to 97%. The relative survival rate for Leukemia declined
7 http://seer.cancer.gov/codrecode/1969+_d09172004/index.html
from 59% to 57%, while the relative survival rate for Non-Hodgkin Lymphoma increased

*Treatment vintage data. *First I will describe the construction of the drug innovation
measure (drug_new%it). A similar approach was used to construct the other innovation
measures. The drug innovation measure was defined as follows:
drug_new%it = ∑p FREQpit POST1990p / ∑p FREQpit
FREQpit = the number of times drug p was used to treat cancer originating at site i
POST1990p = 1 if drug p was approved by the FDA after 1990
Data on utilization of medical procedures and products, by diagnosis and year
(FREQpit), were obtained from the MEDSTAT Marketscan database. MEDSTAT
contains data on outpatient and inpatient services (procedures) and outpatient
prescriptions of hundreds of thousands, or even millions, of individuals.
It is worth distinguishing between two types of drugs: self-administered drugs,
and drugs administered by physicians and other medical providers (e.g., chemotherapy).
Utilization of self-administered drugs is reported in outpatient prescription records
(claims). These records generally don’t include any information about the patient’s
diagnosis. In contrast, drugs that are administered by physicians and other medical
providers are reported as outpatient and inpatient services (procedures). These records
include information about the patient’s diagnosis.
For most diseases other than cancer, the vast majority of drugs are self-
administered, and determining the diagnosis associated with a particular drug’s use
(hence measuring FREQpit) can be difficult. But an important fraction of drug treatments
for cancer are administered by physicians and other medical providers. We will use data
on provider-administered drugs only, since the number of times provider-administered
drug p was used to treat cancer originating at site i in year t can be measured precisely.
Each MEDSTAT outpatient and inpatient service record contains one procedure
code and one or more ICD-9 diagnosis codes. Codes for drugs administered by providers
are Healthcare Common Procedure Coding System (HCPCS) Level II Codes.8 Table 2
shows the top 40 (ranked by frequency) provider-administered drugs associated with all
Only about a third of the drug treatments administered to cancer patients involve
cancer drugs (antineoplastic agents). We will report estimates of two versions of eq. (5):
one does not distinguish between cancer drugs and other drugs, and the other does. Table
3 shows a comparison of the top 40 provider-administered drugs associated with two
major cancer sites (colon and breast) in 2003.
We used Multum’s Lexicon database (http://www.multum.com/Lexicon.htm) to
determine the active ingredients of the drugs corresponding to each of these HCPCS
Level II Codes. We used data from the

[email protected] database
(http://www.fda.gov/cder/drugsatfda/datafiles/default.htm) to determine the year in which
each active ingredient was first approved by the FDA.
The following table shows the mean value of drug_new%, and the number of
provider-administered drugs upon which that statistic is based, for all cancer sites
drug_new% Number of provider-administered Number of firms covered by
8 Level II of the HCPCS is a standardized coding system that is used primarily to identify products, supplies, and services not included in the CPT codes, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's office. Because Medicare and other insurers cover a variety of services, supplies, and equipment that are not identified by CPT codes, the level II HCPCS codes were established for submitting claims for these items. The development and use of level II of the HCPCS began in the 1980's. Level II codes are also referred to as alpha-numeric codes because they consist of a single alphabetical letter followed by 4 numeric digits, while CPT codes are identified using 5 numeric digits. See http://www.cms.hhs.gov/medicare/hcpcs/codpayproc.asp
The fraction of post-1990 drugs increased from 9% in 1992 to 33% in 2003. The
1992 figure is based on 17,731 observations (drug treatments), and the 2003 figure is
based on 486,409 treatments. The increase in sample size is partly due to the fact that the
number of firms covered by the MEDSTAT data increased from 45 in 1992 to 200 in
A similar procedure was used to construct the radiology and surgery innovation
measures (rad_onc_new%it, rad_diag_new%it, and surg_new%it). However, unlike
drugs, radiology and surgical procedures are not subject to FDA approval,9 so FDA
approval dates can’t be used to measure the vintage of these procedures.
Radiology and surgical procedures are coded using Current Procedural
Terminology (CPT) codes that are established and maintained by the American Medical
Association.10 The AMA publishes a database (

*CPT Assistant Archives 1990-2003) *that
provides information about the year in which each CPT code was first established. The
data are left-censored: if a code was established prior to 1990, we know only that it is a
pre-1990 code. To construct the radiology and surgery innovation measures, we defined
POST1990p = 1 if the CPT code for procedure p was established by the AMA after
The radiology and surgery innovation measures are probably less reliable than the
drug innovation measure, because FDA approval of a drug is more meaningful indicator
than AMA establishment of a new CPT code. For example, measuring surgical
innovation using CPT code changes may be problematic. Closer inspection of the data
on surgical procedures reveals that some “new” procedures are probably just relabeled or
reclassified old procedures, rather than true innovations. For example, the three
procedures whose codes were added in 1997 which were most frequently performed in
9 Some new procedures may be closely related to medical device innovations, which are subject to FDA approval, but linking procedure innovations to FDA approvals of medical devices is difficult. 10 For a description of how CPT codes are maintained, the committees involved, and the entire CPT process, including the evolution of CPT, see http://www.ama-assn.org/ama/pub/category/3112.html.
1997 were 98940, 98941, and 98942, which correspond to different types of chiropractic
manipulative treatment of the spine. Undoubtedly, this type of treatment was performed
well before 1997. A new CPT code should therefore be considered a necessary condition
for a medical innovation, but not a sufficient condition: all innovations have new CPT
codes, but some new CPT codes are not innovations. The fraction of procedures with
new CPT codes exceeds the fraction of truly innovative procedures, perhaps by a
significant amount, and the degree of overstatement varies across diseases. In the future,
I hope to develop improved measures of radiology and surgery innovation.
Table 4 presents data on innovation measures in 2003, by cancer site, ranked by

**IV. Estimation issues **

Several issues regarding the estimation of eq. (5) should be considered before we
present the empirical results. These issues are: (1) functional form; (2) measurement
error; (3) weighting; and (4) estimation by cancer stage vs. overall estimation.

*Functional form. *The dependent variable of eq. (5) is specified to be an arbitrary
function of the observed survival rate, f(S). Because the survival rate is bounded between
zero and one, a linear function (e.g., f(S) = S) would not be an appropriate choice. We
will estimate the model using two alternative functional forms. The first is the probit, i.e.
f(S) = F-1(S), where F-1( ) is the inverse of the standard normal cumulative distribution.
The second is the logarithmic, i.e. f(S) = ln(S).11 As shown in eq. (5), the same
transformation is applied to the expected survival rate.

*Measurement error*. As described above, the survival data and the treatment vintage data
were obtained from different data sources and are based on different populations. The
survival data were obtained from SEER 9 public-use data, which primarily covers elderly
people in certain regions of the U.S.12 The treatment vintage data were obtained from the
MEDSTAT Marketscan database, which primarily covers nonelderly people in other
regions of the U.S.13 As rich as the MEDSTAT database is, it provides data on only a
11 F-1(S) is similar to ln(S / (1 – S)). 12 About two-thirds of cancer patients are 65 or over. 13 MEDSTAT has data on some patients in Medicare health plans, but these data were not available for this study.
small proportion of all cancer treatments provided in the U.S. This may be illustrated
with utilization data for a specific drug treatment, an ondansetron HCL injection (HCPCS
code J2405). In 2003 MEDSTAT data, this procedure was performed in connection with
a cancer diagnosis 11,845 times. According to Medicare Part B Physician/Supplier
(http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/Downloads/LEVEL2SERV03.pdf)
there were 6,381,294 allowed services of ondansetron HCL injection in 2003. The
MEDSTAT frequency is only 0.2% of the Medicare frequency.
We assume that treatment innovation indicators based on MEDSTAT data are
useful, albeit noisy, indicators of the treatment innovation experienced by patients in
SEER 9 registries. This sampling error is likely to bias the coefficients on the treatment

*Weighting*. Eq. (5) is to be estimated using grouped data, where groups are defined by
cancer site and year of diagnosis. These groups are very heterogeneous in terms of size,
where size is measured either by number of SEER 9 patients or number of MEDSTAT
treatments. For example, as shown in Table 4, in 2003 there were 140,122 drug
treatments for breast cancer, and only 32 for cancer of the eye and orbit.
We will estimate eq. (5) via weighted least-squares (WLS), where the weight is a
measure of size. Consider two different measures of size: the number of SEER 9
patients, and the number of MEDSTAT drug treatments. In a given year, the correlation
across cancer sites between these two measures is quite high. For example, in 2003 the
correlation between the number of SEER 9 patients and the number of MEDSTAT drug
treatments is about .85. This suggests that the choice between these two weights
wouldn’t make much difference. As noted above, however, the MEDSTAT sample size
increased dramatically over time, suggesting that the more recent innovation measures
are far more reliable, and therefore deserve much greater weight.14
We will estimate eq. (5) with two different sets of weights--the number of SEER
9 patients, and the number of MEDSTAT drug treatments. We believe that the estimates
based on the latter set of weights are more credible.
14 As shown in Table 1, the SEER 9 sample size barely increased over time.

*Estimation: overall vs. by stage. *The SEER microdata contain information about the
stage of cancer at time of diagnosis. Thus, it is feasible to calculate observed and
expected survival rates by cancer site, year,

*and stage*. However, we believe that our
approach (controlling for stage distribution rather than analysis by stage) is preferable,
for two reasons. First, there is no information about cancer stage in MEDSTAT. Hence,
we can’t construct stage-specific treatment innovation measures.
Even if we could construct such measures, due to a phenomenon known as

*stage*
*migration*, analysis by cancer stage is probably inappropriate. Changes in stage-specific
survival may provide a distorted view of true survival change. In particular, the survival
rate for every stage may improve even when overall survival does not change.
The assignment of a given stage to a particular cancer may change over time due
to advances in diagnostic technology. Stage migration occurs when diagnostic procedures
change over time, resulting in an increase in the probability that a given cancer will be
diagnosed in a

*more advanced *stage. For example, certain distant metastases that would
have been undetectable a few years ago can now be diagnosed by a computer tomography
(CT) scan or by magnetic resonance imaging (MRI). Therefore, some patients who would
have been diagnosed previously as having cancer in a

*localized *or

*regional *stage are now
diagnosed as having cancer in a

*distant *stage. The likely result would be to remove the
worst survivors — those with previously undetected distant metastases — from the
localized and regional categories and put them into the distant category. As a result, the
stage-at-diagnosis distribution for a cancer may become less favorable over time, but the
survival rates for each stage may improve: the early stage will

*lose *cases that will survive

*shorter *than those remaining in that category, while the advanced stage will

*gain *cases
that will survive

*longer *than those already in that category. However,

*overall survival *
*would not change *(Feinstein et al., 1985). Stage migration is an important concept to
understand when examining temporal trends in survival by stage at diagnosis as well as
temporal trends in stage distributions; it could affect the analysis of virtually all solid
15

*SEER Cancer Statistics Review 1973-1999 Overview*, p. 12.

**V. Empirical results **

We computed weighted least-squares estimates of 12 versions of eq. (5): three
survival intervals (1-year, 2-year, and 3-year survival), two functional forms (probit and
logarithmic), and two sets of weights (the number of MEDSTAT drug treatments, and the
number of SEER 9 patients diagnosed); 3 * 2 * 2 = 12. Table 5 shows estimates of eq.
(5) for all three survival intervals, based on the probit functional form and weighting by
For all three survival intervals, the coefficient on drug_new% is positive and
significant (p-value < .03). This indicates that the cancer sites whose drug vintage
(measured by the share of post-1990 treatments) increased the most during the 1990s
tended to have larger increases in observed survival rates, ceteris paribus.
None of the coefficients on the diagnostic radiology innovation measure or the
surgery innovation measure are significant. The coefficient on the radiology oncology
innovation measure is positive and significant in the 2-year survival equation, but not in
The coefficients on the expected survival variable F-1(E) are all positive and
significant. This indicates that part of the increase in the observed survival rate of cancer
patients can be attributed to factors that also increased the survival of people who did not
The coefficients on the log of the number of SEER 9 patients diagnosed are also
all positive and significant. This may be capturing the impact of improved (earlier)
detection: one would expect above-average increases in the number of people diagnosed
for cancer sites with the greatest improvements in detection.
The age coefficient is negative and significant in the 1-year survival equation but
insignificant in the other two equations. However, as noted above, the expected survival
rate is based on the age- (as well as race- and sex-) distribution of a comparable set of
people who do not have cancer, so controlling for mean age as well as expected survival
Now let’s consider the stage distribution coefficients. Since survival is inversely
related to disease progression, one might expect the in_situ% coefficient to exceed the
loc_reg% coefficient, and the loc_reg% coefficient to exceed the distant% coefficient.
This is the case in the 2-year and 3-year survival equations, but not in the 1-year
equation. Due to stage migration, however, this ordering is not necessarily to be
expected. Suppose that there was no change in the true stage distribution of any cancer
site, but that some cancer sites had improved detection. These cancer sites would have
the largest increase in distant%, and might also have above-average increases in survival.
The estimates shown in Table 5 do not distinguish between cancer drugs and
other drugs. Table 6 shows the effect of distinguishing between these two types of drugs.
Line 1 of Table 6 shows the estimates of the drug coefficients when cancer drugs and
other drugs are pooled. Lines 2 and 3 show the estimates of the drug coefficients when
cancer drugs and other drugs are disaggregated. In the 1-year and 2-year survival
models, the coefficient on cancer_drug_new% is positive and highly significant, whereas
the coefficient on other_drug_new% is insignificant. This suggests that the gains in
cancer survival are primarily attributable to cancer drugs as opposed to other drugs. In
the 3-year survival model, neither of the coefficients in lines 2 and 3 are significant,
although the coefficient on drug_new% (the utilization-weighted average of
cancer_drug_new% and other_drug_new%) is positive and significant. This may be
attributable to the fact that the 3-year estimates are based on 47% fewer observations
(drug treatments) than the 1-year estimates and 24% fewer than the 2-year estimates. In
the remainder of the paper we will consider models in which cancer drugs and other
As noted above, we also estimated models using an alternative (logarithmic)
functional form, and an alternative set of weights (the number of SEER 9 patients
diagnosed). To conserve space, we will not present the full estimates of these other nine
models. But to enable assessment of the robustness of the estimates, we present in Table
7 the t-statistics (indicating both the sign and statistical significance) on the treatment
innovation measures, F-1(E), ln(N), and age from all 12 models.
The drug vintage coefficient is positive and significant in 11 of the 12 models,
and positive and marginally significant (p-value = .07) in the other model. The only
other variable whose coefficient is generally significant with a consistent sign is the log
of the number of SEER 9 patients diagnosed; this coefficient is positive and significant in
9 of the 12 models. The coefficient on the expected survival term is positive and
significant in only 4 models. The radiation oncology, diagnostic radiology, and surgery
innovation coefficients are positive and significant in 2, 1, and 0 models, respectively.
From our estimates, we can calculate the fraction of the 1992-1999 change in the
observed survival rate that is attributable to the increased utilization of post-1990 drugs,
ceteris paribus. The fraction is equal to
(β1 * (drug_new%1999 - drug_new%1992)) / (f(S1999) – f(S1992))
As noted above, the overall value of drug_new% increased from 9% in 1992 to 29% in
1999, so the above expression reduces to (β1 * 20%) / (f(S1999) – f(S1992)). The following
table shows the observed survival rates for all cancer sites combined in the years 1992
The following table shows estimates from each of the 12 models of the fraction of
the 1992-1999 change in the observed survival rate that is attributable to the increased
Estimates of the fraction of the 1992-1999 change in the observed survival rate that is
attributable to the increased utilization of post-1990 drugs range from 12% to 121%. The
estimated fraction is higher for shorter survival intervals, when observations are weighted
by the number of MEDSTAT drug treatments, and for the logarithmic specification. The
mean of the 12 estimates of the fraction of the 1992-1999 change in the observed survival
rate that is attributable to the increased utilization of post-1990 drugs is 44%.

**Summary and discussion **
Previous studies (Brenner (2002)) have shown that long-term survival rates for
many types of cancer have substantially improved in past decades because of advances in
early detection and treatment. This study has examined the impact of pharmaceutical
innovation and other factors on the survival of U.S. cancer patients during the 1990s. In
particular, it investigated whether cancer survival rates increased more for those cancer
sites that had the largest increases in the proportion of drug treatments that were “new”
treatments. By controlling for “expected survival,” i.e. the survival of a comparable set
of people that did not have cancer, we measured the excess mortality that is associated
with a cancer diagnosis. We also controlled for other types of medical innovation, i.e.
innovation in surgical procedures, diagnostic radiology procedures, and radiation
Data on observed and expected survival rates, the number of people diagnosed,
mean age at diagnosis, and stage distribution were obtained from the National Cancer
Institute’s SEER public-use data. Estimates of rates of innovation in drugs and other
treatment and diagnostic procedures were constructed from the MEDSTAT Marketscan
database and other data sources. Treatment innovation indicators based on MEDSTAT
data are likely to be useful, albeit noisy, indicators of the treatment innovation
experienced by patients in SEER registries. This sampling error is likely to bias the
coefficients on the treatment innovation measures towards zero.
We computed weighted least-squares estimates of 12 versions of a survival
model, based on different survival intervals, functional forms, and sets of weights. The
drug vintage coefficient was positive and significant in almost every model. This
indicates that the cancer sites whose drug vintage (measured by the share of post-1990
treatments) increased the most during the 1990s tended to have larger increases in
observed survival rates, ceteris paribus.
Estimates of the fraction of the 1992-1999 change in the observed survival rate
that is attributable to the increased utilization of post-1990 drugs ranged from 12% to
121%. The estimated fraction is higher for shorter survival intervals, when observations
are weighted by the number of MEDSTAT drug treatments, and for the logarithmic
specification. The mean of the 12 estimates of the fraction of the 1992-1999 change in
the observed survival rate that is attributable to the increased utilization of post-1990
drugs is 44%. Due to sampling and other measurement errors, these estimates may be
The coefficients on measures of other types of medical innovation (in radiation
oncology, diagnostic radiology, and surgery innovation) were generally not significant.
However these measures may be less reliable than the drug innovation measure: they
were based upon the year in which the AMA established a new procedure code, which
may be a far less meaningful indicator of innovation than the year in which the FDA first
approved a drug. This topic warrants further research.

**References **

Axtell LM, Cutler SJ. (1961), “The relative survival rate: A statistical methodology,”

*J *

Natl Cancer Inst Monogr 6, pp. 101-121.

Brenner H. (2002), "Long-term survival rates of cancer patients achieved by the end of

the 20th century: a period analysis,"

*Lancet* Oct 12; 360(9340):1131-5.

Feinstein AR, Sosin DM, Wells CK (1985), “The Will Rogers phenomenon: Stage

migration and new diagnostic techniques as a source of misleading statistics for survival

of cancer,”

*New England Journal of Medicine* 312, pp.1604-1608.

Johnson, John, Grant Williams, and Richard Pazdur, “End points and United States Food

and Drug Administration Approval of Oncology Drugs,”

*Journal of Clinical Oncology* 21

(7), 1 April 2003, pp. 1404-11.

Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G,

Shan J, Rios MB, Champlin R, de Lima M, Cortes J. (2005), “Survival benefit with

imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous

leukemia--comparison with historic experience.”

*Cancer*. May 15; 103(10): 2099-108.

Mosby (2004), Mosby's Drug Consult 2004, 14th Edition,

http://www.mosbysdrugconsult.com/

Richardson PG, et al (2005), “Bortezomib or high-dose dexamethasone for relapsed

multiple myeloma.”

*N Engl J Med.* Jun 16;352(24):2487-98.

von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005), “Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer,”

*J Clin Oncol.* Jul 20; 23(21): 4602-8.

**1992 and 2000 survival data, top 30 (ranked by 1992 incidence) cancer sites**
**Two-year survival rates**
**Observed**
**Expected**
**Relative**
**diagnosed**
**1992 2000 1992 2000 1992**
**Top 40 (ranked by frequency) provider-administered drugs **
**associated with cancer diagnoses in 2003**
**COUNT PERCENT**
**Comparison of top 20 (ranked by frequency) provider-administered drugs associated with two major cancer sites in 2003**
**Colon excluding Rectum**
**COUNT PERCENT**
**COUNT PERCENT**
**Innovation measures in 2003, by cancer site, ranked by number of drug treatments**
**Post-1990 procedures/total procedures**
**Number of procedures**
**Cancer site**
**drugs radiation diagnostic **
**radiation diagnostic surgery**
**oncology**
**radiology**
**oncology**
**radiology**
**Post-1990 procedures/total procedures**
**Number of procedures**
**Cancer site**
**drugs radiation diagnostic **
**radiation diagnostic surgery**
**oncology**
**radiology**
**oncology**
**radiology**
Trachea, Mediastinum and Other Respiratory Organs

**Weighted least-squares estimates of eq. (5), **
**based on probit functional form and weighting by number of MEDSTAT drug treatments**
**1-year survival**
**2-year survival**
**3-year survival**
**Parameter**
**Estimate t-Value Prob > t Estimate t-Value Prob > t Estimate t-Value Prob > t**
The dependent variable is F-1(Sit), where Sit is the observed survival rate of people diagnosed with cancer originating at site i in year t, and F-1( ) is the inverse of the standard normal cumulative distribution. All models include cancer-site fixed effects.

**Distinguishing between cancer drugs and other drugs**
**1-year survival**
**2-year survival**
**3-year survival**
**Line Parameter**
**Estimate t-Value Prob > t Estimate t-Value Prob > t Estimate t-Value Prob > t**
**t-statistics (indicating signs and statistical significance) of estimated coefficients of 12 survival models**
**Survival interval**
**Functional form**
MEDST MEDST MEDST SEER 9 SEER 9 SEER 9 MEDST MEDST MEDST SEER 9 SEER 9 SEER 9 AT drug AT drug AT drug patients patients patients AT drug AT drug AT drug patients patients patients
treatment treatment treatment diagnose diagnose diagnose treatment treatment treatment diagnose diagnose diagnose

**Coefficient**

drug_new%

SEER Cancer Causes of Death Recode 1969+ (9/17/2004)

**Cancer Causes of Death**
**All Malignant Cancers**
**Oral Cavity and Pharynx**

Lip

**Digestive System**

Esophagus

**Respiratory System**

Nose, Nasal Cavity and Middle Ear

**Bones and Joints**
**Skin excluding Basal and Squamous**

Melanoma of the Skin

**Female Genital System**

Cervix Uteri

**Male Genital System**

Prostate

**Urinary System**

Urinary Bladder

**Eye and Orbit**
**Brain and Other Nervous System**
**Endocrine System**

Thyroid

**Lymphoma**

Hodgkin Lymphoma

**Leukemia**

Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Myeloid and Monocytic LeukemiaAcute myeloid
C46+

C26.1, C45.7

**+**, C45.9

**+**, C76-C80,

159.1, 195-199, 202.3, 202.5 C88, C96.0-C96.2, C96.7, C96.9,

**Miscellaneous Malignant Cancer**
http://seer.cancer.gov/codrecode/1969+_d09172004/index.html

Source: http://economics.adelaide.edu.au/events/archive/2007/Pharmaceutical-innovation-and-US-cancer-survival-in-the-1990s-evidence-from-linked-SEER-MEDSTAT-data.pdf

SIVA SIVANI INSTITUTE OF MANAGEMENT From Director’s Desk News Brief 22 -07-2010 __________________________________________________________________ MARKETING 1. Toyota launches diesel variant of Corolla Altis Gearing up for December launch of its small car, Etios. Toyota Kirloskar Motors (TKM) on Wednesday launched the diesel version of its premiumsedan, the Corolla Altis. Priced at

TESTBERICHT RINGANA „Enerchi_ _“ Dartsch Scientific GmbH Oskar-von-Mil er-Str. 10 D-86956 Schongau Institut für zellbiologische Testsysteme A-8230 Hartberg E-Mail [email protected] Internet www.dartsch-scientific.com – Tes tbe richt und Fachinformation – Tierversuchsfreie zellbiologische Untersuchungen zu förderlichen Wirkeffekten von RINGANA „Enerch